Addex Therapeutics Showcases GABAB PAM Data for Chronic Cough
Exciting Developments in Chronic Cough Treatment
Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company specializing in innovative small molecule allosteric modulators for neurological disorders, is set to present groundbreaking preclinical data at the 10th American Cough Conference. This event will take place shortly, and Addex is eager to share insights from their gamma-aminobutyric acid (GABAB) positive allosteric modulator (PAM) cough program.
Presentation Details and Key Insights
Mikhail Kalinichev, Addex's Head of Translational Science, will lead the presentation, focusing on the significant progress of the GABAB PAM cough program. The presentation will include compelling antitussive data derived from in vivo models, showcasing the robust efficacy of their lead drug candidate. This candidate is gearing up to begin Investigational New Drug (IND) enabling studies, marking a significant milestone in its development.
Key Information for Attendees
Mark your calendars for a detailed exploration of the results:
Date: Saturday, June 7, 2025
Time: 11:20 AM EST
Title: Compound A: A Novel Positive Allosteric Modulator of the GABAB Receptor Exhibiting Strong Antitussive Efficacy
Location: Hyatt Regency Dulles, 2300 Dulles Corner Blvd., Herndon, VA, US, 20171
The Role of GABAB Receptors in Cough Treatment
GABAB receptors play a vital role in the regulation of cough. They are widely found across the airways and within the cough neural circuitry's central and peripheral components. Existing research has validated the clinical efficacy of GABAB receptor activation for chronic cough treatment via baclofen, a selective GABAB agonist that binds effectively. However, baclofen’s application is limited due to side effects, short action duration, and diminishing effectiveness over prolonged use. By targeting allosteric sites on the GABAB receptors, Addex aims to overcome these challenges, enhancing tolerability and selectivity without inducing tolerance.
About Addex Therapeutics
Addex Therapeutics is at the forefront of biopharmaceutical innovation, primarily focused on developing small molecule allosteric modulators for neurological conditions. Their lead drug candidate, dipraglurant, is currently being evaluated for its potential in brain injury recovery, including recovery from strokes and traumatic brain injuries. In addition to pursuing its independent GABAB PAM program aimed at chronic cough, Addex has engaged in collaborative efforts for developing a GABAB PAM drug with its partner Indivior. This collaboration is centered on treating substance use disorders and has successfully completed necessary studies for regulatory review.
Investing in Future Modulators
Addex also maintains significant stakes in Neurosterix LLC, a private firm pioneering several allosteric modulator approaches. These include specific programs for treating schizophrenia, mood disorders, and mild neurocognitive disorders. As a publicly traded company on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN", Addex is well-positioned for engagement with investors interested in cutting-edge medical solutions.
Events and Contacts
For those interested in the upcoming conference and further developments in Addex’s research, you can reach out to:
Contact Details:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)7968 022075
Email: msinclair@halsin.com
Frequently Asked Questions
What is GABAB PAM?
GABAB PAM (Positive Allosteric Modulators) are compounds that enhance the activity of GABAB receptors, which are crucial for controlling various neurological activities, including cough reflexes.
What are the benefits of targeting GABAB receptors for cough treatment?
GABAB receptor targeting may produce more effective and tolerable treatments for chronic cough compared to traditional methods, reducing side effects and the development of tolerance.
Where will Addex present its findings?
Addex's findings will be presented at the Hyatt Regency Dulles during the 10th American Cough Conference.
How does Addex differentiate its approach to cough treatment?
Addex's approach focuses on allosteric modulation rather than traditional agonists, potentially offering improved selectivity and a better safety profile for patients.
How can I learn more about Addex Therapeutics?
For more information, visit their official website at www.addextherapeutics.com.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
